Ventyx Biosciences, Inc. (NASDAQ: VTYX)

This lawsuit is for anyone who acquired securities in Ventyx Biosciences, Inc. (NASDAQ: VTYX) securities October 18, 2021 through November 6, 2023.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, in the Prospectus to the Company’s IPO, and throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the Company’s drug, VTX958, was more effective in treating psoriasis than the Company knew the drug to be.

On November 6, 2023, Ventyx announced results from the Phase 2 SERENITY Trial for its plaque psoriasis treatment, VTX958, disclosing that “[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet [the Company’s] internal target to support advancement of VTX958,” and that the trial would be terminated. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume. Then, on November 22, 2023, Ventyx disclosed that the Company’s President and Chief Medical Officer would no longer serve in those roles. On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Ventyx Biosciences, Inc. (NASDAQ: VTYX) securities October 18, 2021 through November 6, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.